Regulators catching up on global enforcement
This article was originally published in Scrip
In the globalisation race, regulation often comes a poor second to commercial enterprise. Certainly where drug quality and safety are concerned, the rapid growth in outsourcing of manufacturing and clinical trials to countries like India and China has left regulators in the US and Europe struggling to ensure that GMP and GCP standards are being met.
You may also be interested in...
France is exploring the use of hydroxychloroquine and lopinavir/ritonavir in COVID-19, but only in hospitalized patients and in clinical trials, and has banned all exports of the products to avoid possible shortages.
Efforts are under way in the UK on many fronts to develop new treatments and vaccines for coronavirus infection, including researching new uses of existing products and clinical trials of new vaccines.
Recommending new medicines for approval and allowing sponsors of others extra time to answer outstanding questions are among the many tasks on the agenda of the March meeting of European Medicines Agency's key scientific committee, the CHMP. The meeting has been taking place, remotely, this week.